Parents united to find a cure
  • Home
  • About Us
    • Mission Statement
    • Our Goal
    • Board of Directors
    • Scientific and Research Advisory Board
    • Strategic Plan
    • Financial Statement
    • What is Sanfilippo Syndrome?
    • Contact Us
  • How You Can Help
    • Donate
    • Host or Attend an Event
    • Products and New Items for sale to promote awareness and serve families!
    • Become an Affiliate
      • Spinning Wheels Productions and Team Sanfilippo Collaboration
  • Research
    • Research Projects
      • Research – Australia
      • Research – Canada
      • Research – France and Netherlands
      • Research – Italy
      • Research – Poland
      • Research – Spain
      • Research – United Kingdom
      • Research – United States
    • Request for Proposals
  • Therapies and Upcoming Treatments
  • Grants
  • News
    • Gene Therapy
    • Press Releases
    • Community News
    • Resource Links
  • Events

Research Projects – Spain

February 15, 2012 by Team Sanfilippo

Sanfilippo C: TBA
University of Barcelona. Department of Genetic
Dr. Daniel Grinberg dgrinberg@ub.edu
Dr. Lluïsa Vilageliu lvilageliu@ub.edu

Gene Therapy Type A
University of Barcelona
Dr. Fatima Bosch fatima.bosch@uab.es

This week in the meeting of The Committee for Orphan Medicinal Products (COMP), has been presented to the European Medicines Agency (EMEA) the drug “Adeno-associated virus vector serotype 9 expressing human sulfamidase for treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome), D. Esteve Labs, S.A. – EMA/OD/171/10)

How You Can Help

There are many ways you can get involved in the great work of our organization:
  • Host or Attend an Event
  • Become an Affiliate
  • Make a Donation

Donate using PayPal or Credit Card

Donate using Network for Good

Learn More About Team Sanfilippo

Team Sanfilippo Foundation Brochure

To view the Team Sanfilippo Foundation Brochure click here.

Join Team Sanfilippo & Follow Us

Return to top of page
Site Map
© 2025 Team Sanfillipo • Log in